Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Disaggregated Amounts of Research and Development Expenses and General and Administrative Expenses

In addition to the significant expense categories included within consolidated net loss presented in the condensed consolidated statements of operations and comprehensive loss, the below table sets forth disaggregated amounts that comprise research and development expenses and general and administrative expenses (in thousands):


	Three Months Ended March 31,
	2026		2025
Research and development:
Direct research and development expenses:
Program costs	$	4,524	$	3,109
Unallocated research and development expenses:
Personnel-related		1,135		874
Stock-based compensation		161		57
Other		141		—
Total research and development expenses	$	5,961	$	4,040
General and administrative:
Personnel-related	$	2,062	$	739
Stock-based compensation		715		—
Consulting and professional services		1,977		1,656
Facilities-related and other		1,364		360
Total general and administrative expenses	$	6,118	$	2,755

ImageneBio, Inc. 10-Q